Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cixutumumab with Chemotherapy and Bevacizumab in Advanced NSCLC
NCT00955305Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Mar 2010
- Primary completion
- Jan 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cixutumumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-free Survival up to 5 years. Started Mar 2010; status: terminated.
02
Drugs
cixutumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00955305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00955305.